BioWorld-International-2007-02-14

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

Billing the investment as the largest venture capital round in German biotechnology since 2001, Immatics Biotechnologies GmbH raised €40 million (US$52.1 million) in a second funding round to further its pipeline of cancer vaccines based on peptides derived from tumor-associated antigens. (BioWorld International)

No Abstract

No Abstract

No Abstract